# A Study Testing the Superiority of CHF 1535 pMDI 800/24µg Total Daily Dose Compared With CHF 718 pMDI 800µg Total Daily Dose in Adults With Asthma on Medium or High-Dose Inhaled Corticosteroid

> **NCT05292586** · PHASE3 · COMPLETED · sponsor: **Chiesi Farmaceutici S.p.A.** · enrollment: 1377 (actual)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** Beclomethasone Dipropionate/Formoterol Fumarate
- **DRUG:** Beclomethasone Dipropionate

## Key facts

- **NCT ID:** NCT05292586
- **Lead sponsor:** Chiesi Farmaceutici S.p.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-08-31
- **Primary completion:** 2024-06-24
- **Final completion:** 2024-06-24
- **Target enrollment:** 1377 (ACTUAL)
- **Last updated:** 2025-09-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05292586

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05292586, "A Study Testing the Superiority of CHF 1535 pMDI 800/24µg Total Daily Dose Compared With CHF 718 pMDI 800µg Total Daily Dose in Adults With Asthma on Medium or High-Dose Inhaled Corticosteroid". Retrieved via AI Analytics 2026-07-02 from https://api.ai-analytics.org/clinical/NCT05292586. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*